Ex-Pfizer researchers bag $27m for ‘not-a-Pfizer-spin-out’
This article was originally published in Scrip
Executive Summary
"This is not a Pfizer spin out," insists Dr Mike Yeadon CEO of new biotech company Ziarco, which has licensed inflammatory and allergic therapeutic candidates from Pfizer and secured a $27 million series A round led by Biotechnology Value Fund and including Pfizer Venture Investments.
You may also be interested in...
Start-Up Quarterly Statistics, Q4 2016
A review of biopharma start-up dealmaking and financing from October through December 2016, based on data from Strategic Transactions.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.